CATALYSTYahoo • 11d ago
ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.
Why ICCC Stock dropped -2.82% Today — RQD Quant Desk Flash
$10.32 -2.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $10.25
ImmuCell Corporation (ICCC) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $93.7M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $10.25 (-0.70%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 4.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-3.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ICCC)Realized 20D OHLCV Swing Band: ±4.9%
Deterministic 5-Pillar Attribution (50/100 Composite)
🔍 WHY ICCC SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (26% of score)
Altman Z-Score 4.28 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (24% of score)
FRED Regime × Technicals: 77% of 52W Range • RSI-14 at 50.5 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$9.80+9.7% Next Q
42
Q2 (-2Q)Grade D$10.75-4.7% Next Q
45
Q3 (-1Q)Grade D$10.25+0.7% Next Q
47
CurrentGrade D$10.32-1.4% Hist 90D α
50
Trajectory: D (42) → D (50)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ICCC Turnaround Squeeze
While ICCC currently carries a cautious 50/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.04) and Max Pain ($10.84) forces dealer call-delta covering toward $12.71.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+1.08% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICCC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ICCC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ICCC Stock dropped -2.82% Today — RQD Quant Desk Flash
ImmuCell Corporation (ICCC) dropped -2.82% to $10.32, trading at 77% of its 52-week range ($4.52 – $12.1). Stretched risk/reward at current multiples (4% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 77% of its 52-week range ($4.52 – $12.1) with RSI-14 at 50.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.9% around $10.32 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 41.4% gross margin and $1.2M annual free cash flow.
Live ICCC Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ICCC)
- ✓Walkthrough of ICCC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ICCC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.99%📐 WEDGE COMPRESSION COIL
2026-10-30O $10.25H $10.40L $9.98C $10.32VOL 11.0K
RES: $10.78SUP: $9.64SMA50: $10.04SMA200: $8.86
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ICCC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
33.5%/yr Implied 5Y Growth
vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ICCC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ICCC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ICCC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICCC)
Health Care Rank #349 of 1016
⚔️ IMDX vs ICCC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ICCC vs. IMDX, TKNO, NNNN, MYGN)
Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ImmuCell Corporation (ICCC) ranks #349 by composite RQD confidence (50/100, grade D) and #669 by equity capitalization ($93.7M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. ICCC currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ICCC
ACTIVE
ImmuCell Corporation | D | 50/100 | — | 41.4% | 4.2% | -2.82% | $93.7M | Benchmark Subject |
| IMDX Insight Molecular Diagnostics Inc. | E | 31/100 | — | 56.7% | -35.0% | 0.00% | $104.1M | /imdx-vs-iccc → |
| TKNO Alpha Teknova Inc. | D | 44/100 | — | 33.2% | -21.3% | +2.93% | $499.2M | /tkno-vs-iccc → |
| NNNN Anbio Biotechnology (Class A) | D | 45/100 | 83.6x | 87.2% | 17.0% | -3.12% | $535.3M | /nnnn-vs-iccc → |
| MYGN Myriad Genetics Inc. | D- | 39/100 | — | 69.9% | -35.0% | +0.60% | $638.0M | /mygn-vs-iccc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000811641In its most recent audited fiscal period (FY2025, filed 2025-12-31), ImmuCell Corporation (ICCC) reported GAAP revenue of $27.6M (+4.3% vs. FY2024 revenue of $26.5M , and +58.2% cumulative change since FY2023) , GAAP net income of -$1.0M, operating cash flow of $2.5M, and free cash flow of $1.2M (+1236.0% YoY). On the balance sheet, ICCC closed FY2025 with $42.5M in total assets against $7.5M in total debt (Altman Z-Score: 4.28, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $27.6M | -$1.0M | $2.5M | $1.2M | $42.5M | $7.5M |
| FY2024 (FY) | 2024-12-31 | $26.5M | -$2.2M | $357.9K | -$107.8K | $45.1M | $9.0M |
| FY2023 (FY) | 2023-12-31 | $17.5M | -$5.8M | -$4.7M | -$4.7M | — | — |
3. ICCC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ICCC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, ImmuCell Corporation (NASDAQ: ICCC) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $10.32 (-2.82% 1D, market cap $93.7M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, ICCC ranks #349 in composite RQD confidence.
How does ICCC compare to IMDX and TKNO in the Health Care sector?
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ICCC carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 41.4%, and ROIC of 4.2%. By comparison, IMDX (Insight Molecular Diagnostics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $104.1M) and TKNO (Alpha Teknova Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.3%, cap $499.2M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ICCC?
Per ICCC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000811641), ImmuCell Corporation generated $27.6M in revenue (+4.3% YoY), -$1.0M in net income, and $1.2M in free cash flow against $42.5M in total assets and $7.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ICCC trading relative to its 50-day, 200-day, and 52-week technical levels?
ICCC last traded at $10.32 (-2.82% on volume of 3,319 shares), positioning the stock +2.79% above its 50-day simple moving average ($10.04) and +16.48% above its 200-day simple moving average ($8.86). Across its 52-week range of $4.52 to $12.10, ICCC sits at the 76.5% percentile with a 14-day RSI of 50.5 (NEUTRAL RANGE) and an implied next-earnings move of ±4.9% ($9.81 to $10.83).
ICCC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ICCC stock moving today?
Why ICCC Stock dropped -2.82% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (4% return on capital) under elevated 10-year interest-rate pressure.